S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
NASDAQ:MEIP

MEI Pharma Stock Forecast, Price & News

$2.99
+0.11 (+3.82 %)
(As of 01/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.86
Now: $2.99
$2.99
50-Day Range
$2.64
MA: $2.86
$3.22
52-Week Range
$0.72
Now: $2.99
$4.46
Volume442,043 shs
Average Volume840,593 shs
Market Capitalization$336.44 million
P/E RatioN/A
Dividend YieldN/A
Beta1.65
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.
MEI Pharma logo

MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

203rd out of 1,922 stocks

Pharmaceutical Preparations Industry

102nd out of 769 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEIP
Previous SymbolNASDAQ:MSHL
CUSIPN/A
Phone858-369-7100
Employees51

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$28.91 million
Book Value$0.74 per share

Profitability

Net Income$-46,010,000.00
Net Margins-142.81%

Miscellaneous

Market Cap$336.44 million
Next Earnings Date2/4/2021 (Estimated)
OptionableOptionable
$2.99
+0.11 (+3.82 %)
(As of 01/22/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MEIP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

How has MEI Pharma's stock price been impacted by Coronavirus?

MEI Pharma's stock was trading at $1.55 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MEIP shares have increased by 92.9% and is now trading at $2.99.
View which stocks have been most impacted by COVID-19
.

Is MEI Pharma a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MEI Pharma stock.
View analyst ratings for MEI Pharma
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than MEI Pharma?

Wall Street analysts have given MEI Pharma a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but MEI Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release its next quarterly earnings announcement on Thursday, February 4th 2021.
View our earnings forecast for MEI Pharma
.

How were MEI Pharma's earnings last quarter?

MEI Pharma, Inc. (NASDAQ:MEIP) issued its earnings results on Tuesday, November, 10th. The company reported ($0.25) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.18. The company had revenue of $3.83 million for the quarter, compared to the consensus estimate of $2.48 million. MEI Pharma had a negative net margin of 142.81% and a negative trailing twelve-month return on equity of 33.55%.
View MEI Pharma's earnings history
.

What price target have analysts set for MEIP?

7 analysts have issued twelve-month target prices for MEI Pharma's stock. Their forecasts range from $9.00 to $13.00. On average, they anticipate MEI Pharma's stock price to reach $10.60 in the next year. This suggests a possible upside of 254.5% from the stock's current price.
View analysts' price targets for MEI Pharma
or view Wall Street analyst' top-rated stocks.

Who are some of MEI Pharma's key competitors?

What other stocks do shareholders of MEI Pharma own?

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the following people:
  • Dr. Daniel P. Gold, Pres, CEO & Director (Age 67, Pay $1.14M)
  • Mr. Brian G. Drazba B.A., CPA, CPA, CFO & Sec. (Age 60, Pay $603k)
  • Mr. David M. Urso B.A., Esq., J.D., COO & Gen. Counsel (Age 57, Pay $718.75k)
  • Dr. Robert D. Mass, Chief Medical Officer (Age 67, Pay $294.59k)
  • Mr. David A. Walsey J.D., L.L.M., VP of IR & Corp. Communications
  • Mr. Brian T. Powl, Sr. VP of Marketing
  • Dr. Ofir Moreno, Sr. VP of Pharmaceutical Sciences
  • Dr. Karen E. Potts Ph.D., Sr. VP of Regulatory Affairs (Age 58)
  • Dr. Richard G. Ghalie, Sr. VP of Clinical Devel. (Age 63)

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by many different institutional and retail investors. Top institutional investors include DAVENPORT & Co LLC (0.08%). Company insiders that own MEI Pharma stock include Brian G Drazba, Christine Anna White, Daniel P Phd Gold and Thomas C Reynolds.
View institutional ownership trends for MEI Pharma
.

Which institutional investors are buying MEI Pharma stock?

MEIP stock was acquired by a variety of institutional investors in the last quarter, including DAVENPORT & Co LLC. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, and Thomas C Reynolds.
View insider buying and selling activity for MEI Pharma
or or view top insider-buying stocks.

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $2.99.

How big of a company is MEI Pharma?

MEI Pharma has a market capitalization of $336.44 million and generates $28.91 million in revenue each year. The company earns $-46,010,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. MEI Pharma employs 51 workers across the globe.

What is MEI Pharma's official website?

The official website for MEI Pharma is www.meipharma.com.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.